Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTT1057 PET Imaging in Renal Cell Carcinoma
NCT03427476Phase 1Completed
- Sponsor
- Cancer Targeted Technology
- Start
- Jan 2018
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial (2 arms), sponsored by Cancer Targeted Technology. Primary endpoint: Adverse event frequency at 7 days. Started Jan 2018; status: completed.
Beyond the preview
Go deeper on NCT03427476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427476.